Theodore Leng, MD, FACS

The American Academy of Ophthalmology IRIS Registry contains 367 million patient encounters from more than 65 million unique patients.

On March 18, 2020, the American Academy of Ophthalmology issued guidance regarding the emerging COVID-19 pandemic, stating that ophthalmologists should “cease providing any treatment other than urgent or emergent care immediately.”

In June 2012, the iStent from Glaukos was approved by the FDA. Approval for the iStent inject followed in 2018.

The American Academy of Ophthalmology IRIS Registry is a centralized data repository that leverages the expanded use of electronic health records to collect real-world data that can be used to improve patient care and outcomes.

In this Healio Video Perspective from the virtual AAO annual meeting, Steven D. Schwartz, MD, and Theodore Leng, MD, FACS, discuss insights gleaned about ophthalmic care during the pandemic from examining the IRIS Registry.

NEW ORLEANS ― At the American Academy of Ophthalmology meeting here, Theodore Leng, MD, discusses a poster presentation reviewing the treatment of branch retinal vein occlusion and central retinal vein occlusion among the three anti-VEGF agents at 6 months. The study showed similar treatment outcomes for bevacizumab, ranibizumab and aflibercept.